|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.08.25 - 19:45
|
What Makes Sangamo (SGMO) a New Buy Stock (Zacks)
|
|
|
Sangamo (SGMO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.05.25 - 00:27
|
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering (Business Wire)
|
|
|
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants to purchase 34,398,393 shares of its common stock, together with accompanying warrants to purchase 46,633,393 shares of its common stock. The combined offering price of each share of common stock and accompanying warrant is $0.50. The combined offering price of each pre-funded warrant and accompanying warrant is $0.49. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $0.75 per share, will become exercisable six months from the date of issuance and will expire six years from the date of issuance. All of the securities in the offering are to be sold by Sangamo. The offerin...
|
|
|
13.05.25 - 00:27
|
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results (Business Wire)
|
|
|
Announced capsid license agreement with Lilly to deliver genomic medicines for up to five central nervous system (CNS) disease targets. Received $18 million upfront license fee for first target and eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments, plus tiered royalties on potential net sales.
Announced derisking milestones in pathway to anticipated biologics license application (BLA) submission for isaralgagene civaparvovec in Fabry disease, including all patients having passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway, and productive Type B Chemistry, Manufacturing and Controls (CMC) meeting with FDA.
Announced participation at 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, including platform presentation in prestigious Presidential Symposium to showcase nonclinical proof of concept in prion disease.
Announced pricing of $23 million underwritten registered direct equ...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
